AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
Abroad (travel likely)RecruitingPHASE2
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Nepean Lung and Sleep, Kingswood, New South Wales, Australia
Dynamic Drug Advancement, Ajax, Ontario, Canada
CIC Mauricie, Trois-Rivières, Quebec, Canada